Protagonist Therapeutics (PTGX) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 3[1], 1 Phase 1[2].
Trial NCT06033586[4] evaluates Open-label rusfertide in Polycythemia Vera with a target enrollment of 46 participants. Trial NCT05210790[5] evaluates Placebo in Polycythemia Vera with a target enrollment of 293 participants.
PTGX has 4 Form 4 insider filings recorded at the SEC in the past 30 days[6].